EGFR and cancer: For cancer, Hasegawa et al. reported that SP-D inhibited the proliferation and motility of NSCLC by binding to epidermal growth factor receptor (EGFR) directly [9], so serum SP-D levels may predict the response to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) [10].